Instrument Inactif

Communiqués Lipum AB

Actions

LIPUM

SE0015660899

Produits pharmaceutiques

Communiqués

20/03	The merger between Flerie and Lipum has been completed	AQ
12/03	The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum	AQ
10/03	Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant	AQ
10/03	Lipum selected for Horizon Europe grant	AQ
26/02	Lipum (Q4 Reviev): Approaching merger completion	AQ
25/02	Lipum AB – Year-end report 2025	AQ
29/12	Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 29 December 2025 at 10:00 CET	AQ
11/12	Flerie receives FDI-approval for the merger with Lipum	AQ
08/12	Flerie publishes merger document	AQ
28/11	Lipum: Merging with Flerie	AQ
27/11	Lipum (Q3 review) - Going private	AQ
27/11	Lipum steps up ahead of phase II – clear signals in Q3	AQ
27/11	Lipum AB – interim report Q3 for the period July-September 2025	AQ
26/11	Notice of extraordinary general meeting of Flerie AB (publ)	AQ
20/11	Lipum’s CEO on the merger with Flerie and the path toward phase II	AQ
18/11	STATEMENT BY THE BOARD OF DIRECTORS OF LIPUM IN VIEW OF THE MERGER OFFER BY FLERIE	AQ
18/11	Flerie and Lipum have agreed on a merger plan	AQ
30/10/25	Lipum presents new topline data supporting BSSL’s role in rheumatoid arthritis	AQ
07/10/25	Lipum gears up with new CFO – one month into the assignment	AQ
01/09/25	Lipum: Finding financial support	AQ
29/08/25	Focus on preparation for Lipum during Q2	AQ
28/08/25	Lipum Q2 - Focus on securing funding	AQ
28/08/25	Lipum AB – interim report Q2 for the period January-June 2025	AQ
07/08/25	Lipum Welcomes Tobias Helgesson as New Chief Financial Officer	AQ
01/08/25	Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025	AQ